{"id":842856,"date":"2025-04-28T16:28:08","date_gmt":"2025-04-28T20:28:08","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/foghorn-therapeutics-presents-new-preclinical-data-on-selective-smarca2-inhibitor-fhd-909-and-selective-cbp-and-selective-ep300-degrader-programs-and-provides-pipeline-update\/"},"modified":"2025-04-28T16:28:08","modified_gmt":"2025-04-28T20:28:08","slug":"foghorn-therapeutics-presents-new-preclinical-data-on-selective-smarca2-inhibitor-fhd-909-and-selective-cbp-and-selective-ep300-degrader-programs-and-provides-pipeline-update","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/foghorn-therapeutics-presents-new-preclinical-data-on-selective-smarca2-inhibitor-fhd-909-and-selective-cbp-and-selective-ep300-degrader-programs-and-provides-pipeline-update\/","title":{"rendered":"Foghorn Therapeutics Presents New Preclinical Data on Selective SMARCA2 Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Programs and Provides Pipeline Update"},"content":{"rendered":"
\n

– FHD-909 (LY4050784) advancing in Phase 1 trial in SMARCA4 (BRG1) mutated cancers, with non-small cell lung cancer (NSCLC) as the primary target population<\/em><\/p>\n

\n – Preclinical synergistic anti-tumor activity of FHD-909 in combination with pembrolizumab and KRAS inhibitors supports clinical exploration<\/em>\n <\/p>\n

\n – <\/em>
\n Selective CBP degrader combination approaches show promise in preclinical ER+ breast cancer models <\/em>\n <\/p>\n

\n
\n –<\/em>
\n <\/strong>
\n Further preclinical characterization of the therapeutic potential of the Selective EP300 degrader program to treat advanced hematological malignancies<\/em><\/p>\n

Virtual investor event Tuesday, April 29, 2025, at 8 a.m. ET <\/em>\n <\/p>\n

CAMBRIDGE, Mass., April 28, 2025 (GLOBE NEWSWIRE) — Foghorn\u00ae<\/sup> Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced new preclinical data for potential first-in-class medicines, including FHD-909, a SMARCA2 (BRM) selective inhibitor, and the Selective CBP degrader program at the 2025 American Association for Cancer Research (AACR) Annual Meeting. A poster on the Selective EP300 degrader program will be presented on Wednesday, April 30, 2025. Foghorn management will hold a virtual investor event on Tuesday April 29, 2025, at 8 a.m. ET to review important pipeline updates.<\/p>\n

\u201cWe are excited by the preclinical combination data of FHD-909, a first-in-class oral selective SMARCA2 inhibitor, with chemotherapy, KRAS inhibitors and pembrolizumab, which support further clinical exploration in NSCLC,\u201d said Adrian Gottschalk, President and Chief Executive Officer of Foghorn. \u201cBuilding on the robust preclinical monotherapy activity we previously reported, new combination data was presented as part of an oral presentation at this year\u2019s AACR annual meeting. Enrollment and dose escalation continue in the ongoing Phase 1 trial evaluating FHD-909. We look forward to continued progress on our FHD-909 program in collaboration with Lilly.\u201d<\/p>\n

Mr. Gottschalk continued, \u201cFor our Selective CBP degrader program, we presented initial preclinical data defining combination opportunities that support potential beyond EP300-mutant cancers, including data in ER+ breast cancer. On Wednesday this week, we will present preclinical findings further characterizing the therapeutic potential of our Selective EP300 degrader program to treat hematological malignancies. And tomorrow during our investor event, we will provide an overview of our Selective ARID1B degrader program, a synthetic lethal target implicated in up to 5% of all solid tumors, to set the stage for a program update expected in the second half of the year. It has been a productive start to 2025, and we look forward to continued progress over the next 12 months.\u201d<\/p>\n

\n Presentation Highlights<\/strong>\n <\/p>\n

\n FHD-909 (LY4050784) Program \u2013 In Collaboration with Lilly<\/strong>\n <\/p>\n

\n
\n Oral Presentation Title:\u00a0LY4050784, a Selective Inhibitor of SMARCA2, Demonstrates Synergistic Activity in Combinations with Pembrolizumab or KRAS Inhibitors<\/em>
\n <\/strong>\n <\/p>\n

\n Enhanced anti-tumor activity with FHD-909 in combination with standard-of-care chemotherapies, anti-PD-1 pembrolizumab and several novel KRAS inhibitors in NSCLC animal models warrants clinical exploration. <\/strong>Selectively blocking SMARCA2 activity is a promising synthetic lethal strategy intended to induce tumor death while sparing healthy cells. SMARCA4 is mutated in up to 10% of NSCLC alone and frequently co-occurs with KRAS mutations, resulting in poor clinical outcomes upon treatment with KRAS or checkpoint inhibitors.<\/p>\n